Navigation Links
Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat

INDIANAPOLIS and PHOENIX, June 2 /PRNewswire/ -- Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), and World Wide Wheat (W3) LLC of Phoenix, Arizona, announced today a collaboration agreement for the development and commercialization of advanced germplasm and traits in wheat.

The concept of the collaboration is to couple Dow AgroSciences' expertise in seeds and traits with W3's proprietary wheat germplasm and robust breeding capabilities. Dow AgroSciences' experience in seed and trait commercialization will be leveraged to bring the next generation of wheat to market. W3 brings more than 40 years of plant breeding to the collaboration and will be able to leverage Dow AgroSciences' reach in key global markets such as North America, Latin America, Europe and Australia.

"We are very pleased to be working with W3, an industry leader in wheat breeding, to launch a portfolio of new products in the near future," said Jerome Peribere, president and CEO of Dow AgroSciences. "This collaboration will build upon our current seed portfolio by expanding into wheat -- a very important global crop which supplies a significant amount of the daily nutrition in human diets. And, we look forward to utilizing our R&D breeding and trait technologies such as EXZACT(TM) Precision Technology to bring advancements in productivity and quality to market."

"We are excited to collaborate with Dow AgroSciences, a significant player in seeds and traits," said Sheldon Richardson, chairman and CEO of W3. "With Dow AgroSciences as our partner, we can leverage customer relationships within the food chain and their marketing and commercialization expertise. Our four decades of plant breeding experience brings a wide diversity of germplasm offering of high yielding varieties developed for markets around the world."

About World Wide Wheat (W3)

World Wide Wheat (W3), headquartered in Phoenix, is one of the world's leading independent plant breeding companies whose research is devoted to the improvement of wheat, barley and oats - major food crops of the world. World Wide Wheat operates research stations in 18 countries, producing superior varieties of cereal grains that are not genetically modified. For more information see

About Dow AgroSciences

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $4.5 billion. Learn more at

SOURCE Dow AgroSciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):